Silymarin loaded liposomes for hepatic targeting: In vitro evaluation and HepG2 drug uptake

European Journal of Pharmaceutical Sciences

Volumn 50, Issue 2, 2013, Pages 161-171

  Elmowafy, Mohammed ^a,b   Viitala, Tapani ^a   Ibrahim, Hany M ^b   Abu Elyazid, Sherif K ^b   Samy, Ahmed ^b   Kassem, Alaa ^b   Yliperttula, Marjo ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

^b Al Azhar University   (Egypt)

Author keywords

Hepatic targeting; HepG2; Silymarin; Targeting liposomes; Sitosterol D glucoside

Indexed keywords

4 (2 HYDROXYETHYL) 1 PIPERAZINEETHANESULFONIC ACID; BETA DEXTRO GLUCOSIDE; CHOLESTEROL; GLUCOSIDE; LIPOSOME; PHOSPHATIDYLCHOLINE; PLASMA PROTEIN; POLYSORBATE 80; SILYMARIN; SITOSTEROL; UNCLASSIFIED DRUG;

ARTICLE; CELL STRAIN HEPG2; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG RELEASE; DRUG SOLUBILITY; DRUG STORAGE; DRUG UPTAKE; HEMOLYSIS; IN VITRO STUDY; LIPID MEMBRANE; PRIORITY JOURNAL; ROOM TEMPERATURE;

HEPATIC TARGETING; HEPG2; SILYMARIN; TARGETING LIPOSOMES; Β-SITOSTEROL Β-D-GLUCOSIDE;

CHOLESTEROL; ERYTHROCYTES; HEMOLYSIS; HEP G2 CELLS; HUMANS; LIPOSOMES; LIVER; PHOSPHATIDYLCHOLINES; PHOSPHATIDYLETHANOLAMINES; POLYETHYLENE GLYCOLS; PROTECTIVE AGENTS; SERUM ALBUMIN, BOVINE; SILYMARIN; SITOSTEROLS;

EID: 84881181698     PISSN: 09280987     EISSN: 18790720     Source Type: Journal    
DOI: 10.1016/j.ejps.2013.06.012     Document Type: Article

References (58)

1. Alexis, F., Pridgen, E., Molnar, L.K., Farokhzad, O.C., 2008. Factors affecting the clearance and biodistribution of polymeric nanoparticles. Mol. Pharm. 5, 505-515.
2. Allen, T.M., Hansen, C., Rutledge, J., 1989. Liposomes with prolonged circulation times: factors affecting uptake by reticuloendothelial and other tissues. Biochim. Biophys. Acta 981, 27-35. (Pubitemid 19127766)
3. Amin, K., Dannenfelser, R.-M., 2006. In vitro hemolysis: guidance for the pharmaceutical scientist. J. Pharm. Sci. 95, 1173-1176. (Pubitemid 43874434)
4. Annesini, M.C., Memoli, A., Petralito, S., 2000. Kinetics of surfactant-induced release from liposomes: a time-dependent permeability model. J. Membrane Sci. 180, 121-131.
5. Bendas, G., Rothe, U., Scherphof, G.L., Kamps, J.A.A.M., 2003. The influence of repeated injections on pharmacokinetics and biodistribution of different types of sterically stabilized immunoliposomes. Biochim. Biophys. Acta 1609, 63-70. (Pubitemid 36044066)
6. Bhardwaj, U., Burgess, D.J., 2010. A novel USP apparatus 4 based release testing method for dispersed systems. Int. J. Pharm. 388, 287-294.
7. Bhattacharya, M., Malinen, M.M., Lauren, P., Lou, Y.-R., Kuisma, S.W., Kanninen, L., Lille, M., Corlu, A., GuGuen-Guillouzo, C., Ikkala, O., Laukkanen, A., Urtti, A., Yliperttula, M., 2012. Nanofibrillar cellulose hydrogel promotes threedimensional liver cell culture. J. Contr. Rel. 164, 291-298.
8. Blumenthal, M., Goldberg, A., Brinkmann, J., 2000. Herbal Medicine, Integrative Medicine Communications. Newton.
9. Carini, R., Comogoliom, A., Albano, A., Poli, G., 1992. Lipid peroxidationand irreversible damage in the rat hepatocyte model. Biochem. Pharmacol. 43, 2111-2115.
10. Chen, J., Cheng, D., Li, J., Wang, Y., Guo, J.-X., Chen, Z.-P., Cai, B.-C., Yang, T., 2013. Influence of lipid composition on the phase transition temperature of liposomes composed of both DPPC and HSPC. Drug Dev. Ind. Pharm. 39, 197-204.
11. Chen, W., Gu, B., Wang, H., Pan, J., Lu, W., Hou, H., 2008. Development and evaluation of novel itraconazole-loaded intravenous nanoparticles. Int. J. Pharm. 362, 133-140.
12. Comoglio, A., Tomasi, A., Malandrino, S., Poli, G., Albano, E., 1995. Scavenging effect of silipide, a new silybin-phospholipid complex on ethanol-derived free radicals. Biochem. Pharm. 50, 1313-1316.
13. Dasgupta, P., Bachhawat, B.K., 1985. Receptor-mediated uptake of asialoganglioside liposomes: sub-cellular distribution of the liposomal marker in isolated liver cell types. Biochem. Int. 10, 327-336. (Pubitemid 15100213)
14. Dixit, N., Baboota, S., Kohli, K., Ahmad, S., Ali, J., 2007. Silymarin: a review of pharmacological aspects and bioavailability enhancement approaches. Indian J. Pharmacol. 39, 171-179.
15. El-Samaligy, M.S., Afifi, N.N., Mahmoud, E.A., 2006a. Evaluation of hybrid liposomes encapsulated silymarin regarding physical stability and in vivo performance. Int. J. Pharm. 319, 121-129. (Pubitemid 44051811)
16. El-Samaligy, M.S., Afifi, N.N., Mahmoud, E.A., 2006b. Increasing bioavailability of silymarin using a buccal liposomal delivery system: Preparation and experimental design investigation. Int. J. Pharm. 308, 140-148. (Pubitemid 43097245)
17. Gabetta, B., Bombardelli, E., Pifferi, G., 1988. Complexes of Flavanolignans with Phospholipids, Preparation There of and Associated Pharmaceutical Compositions. US Patent 4764508, 16 August.
18. Giacomelli, S., Gallo, D., Apollonio, P., Ferlini, C., Distefano, M., Morazzoni, P., Riva, A., Bombardelli, E., Mancuso, S., Scambia, G., 2002. Silybin and its bioavailable phospholipid complex (IdB 1016) potentiate in vitro and in vivo the activity of cisplatin. Life Sci. 70, 1447-1459. (Pubitemid 34159100)
19. Giorgi, R., Conti, M., Pifferi, G., 1989. Soluble Derivatives of Silybin, a Method of Preparing Them, and Pharmaceutical Compositions Containing Them. US Patent 4886791, 12 December.
20. Guhagarkara, S.A., Gaikwad, R.V., Samad, A., Malshec, V.C., Devarajana, P.V., 2010. Polyethylene sebacate-doxorubicin nanoparticles for hepatic targeting. Int. J. Pharm. 401, 113-122.
21. Hee, H.D., Byung, S.C., Ho, C.S., 2006. Doxorubicin encapsulated thermosensitive liposome modified with poly (N-isopropylacrylamide-co- acrylamide): drug release behavior and stability in presence of serum. Eur. J. Pharm. Biopharm. 62, 110-116.
22. Higuchi, T., 1963. Mechanism of sustained action medication. J. Pharm. Sci. 52, 1145-1149.
23. Hirabayashi, H., Nishikawa, M., Takakura, Y., Hashida, M., 1996. Development and pharmacokinetics of galactosylated poly-L-glutamic acid as a biodegradable carrier for liver-specific drug delivery. Pharm. Res. 13, 880-884. (Pubitemid 26227745)
24. Hwang, J.-S., Tsai, Y.-L., Hsu, K.-C., 2010. The feasibility of antihypertensive oligopeptides encapsulated in liposomes prepared with phytosterols-βsitosterol or stigmasterol. Food Res. Int. 43, 133-139.
25. Hwang, S.H., Hayashi, K., Takayama, K., Maitani, Y., 2001. Liver-targeted gene transfer into a human hepatoblastoma cell line and in vivo by sterylglucoside containing cationic liposomes. Gene Ther. 8, 1276-1280. (Pubitemid 32780817)
26. Ishihara, H., Hayashi, Y., Hara, T., Aramaki, Y., Tsuchiya, S., Koike, K., 1991. Specific uptake of asialofetuin-tacked liposomes encapsulating interferon-gamma by human hepatoma cells and its inhibitory effect on hepatitis B virus replication. Biochem. Biophys. Res. Commun. 174, 839-845.
27. Kallinteri, P., Liao, W.Y., Antimisiaris, S.G., Hwang, K.H., 2001. Characterization, stability and in-vivo distribution of asialofetuin glycopeptide incorporating DSPC/CHOL liposomes prepared by mild cholate incubation. J. Drug Target. 9, 155-168. (Pubitemid 32725452)
28. Kawano, K., Nakamura, K., Hayashi, K., Nagai, T., Takayama, K., Maitani, Y., 2002. Liver targeting liposomes containing beta-sitosterol glucoside with regard to penetration-enhancing effect on HepG2 cells. Biol. Pharm. Bull. 25, 766-770. (Pubitemid 40036713)
29. Kim, C.-E., Lim, S.-K., Kim, J.-S., 2012. In vivo antitumor effect of cromolyn in PEGylated liposomes for pancreatic cancer. J. Control. Release 157, 190-195.
30. Kvasnicka, F., Biba, B., Sevcik, R., Voldrich, M., Kratka, J., 2003. Analysis of the active components of silymarin. J. Chromatogr. A 990, 239-245. (Pubitemid 36293880)
31. Li, S.-D., Huang, L., 2008. Pharmacokinetics and biodistribution of nanoparticles. Mol. Pharm. 5, 496-504.
32. Luper, S., 1998. A review of plants used in the treatment of liver diseases: part 1. Altern. Med. Rev. 3, 410-421. (Pubitemid 128709687)
33. Madaus, R., Halbach, G., Trost, W., 1976. Salt of the Silymarin Group with Aminopolyhydroxy Alcohols. US Patent 3994925, 30 November.
34. Maitani, Y., Kawanoa, K., Yamadab, K., Nagai, T., Takayama, K., 2001. Efficiency of liposomes surface-modified with soybean-derived sterylglucoside as a liver targeting carrier in HepG2 cells. J. Control. Release 75, 381-389. (Pubitemid 32727267)
35. Mastrobattistaa, E., Koning, G.A., Storma, G., 1999. Immunoliposomes for the targeted delivery of antitumor drugs. Adv. Drug Deliv. Rev. 40, 103-127. (Pubitemid 29486607)
36. McMullen, T.P.W., Lewis, R.N.A.H., McElhaney, R.N., 1993. Differential scanning calorimetric study of the effect of cholesterol on the thermotropic phase behavior of a homologous series of linear saturated phosphatidylcholines. Biochemistry 32, 516-522. (Pubitemid 23034888)
37. Muller, H., Willis, K.M., 1993. Surface modification of i.v. injectable biodegradable nanoparticles with poloxamer polymers and poloxamine. Int. J. Pharm. 89, 25-31.
38. New, R.R.C., 1990. Liposomes: A Practical Approach. Oxford University Press, Oxford.
39. Oldfield, E., Chapman, D., 1972. Dynamics of lipids in membranes: heterogeneity and the role of cholesterol. FEBS Lett. 23, 285-297.
40. Owens III, D.E., Peppas, N.A., 2006. Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. Int. J. Pharm. 307, 93-102. (Pubitemid 41773257)
41. Park, Y.S., 2002. Tumor-directed Targeting of Liposomes. Biosci. Rep. 22, 267-281. (Pubitemid 35222735)
42. Popielarski, S.R., Hu-Lieskovan, S., French, S.W., Triche, T.J., Davis, M.E., 2005. A nanoparticle-based model delivery system to guide the rational design of gene delivery to the liver. 2. In vitro and in vivo uptake results. Bioconjug. Chem. 16, 1071-1080. (Pubitemid 41368107)
43. Ramana, L.N., Sharma, S., Sethuraman, S., Ranga, U., Krishnan, U.M., 2012. Investigation on the stability of saquinavir loaded liposomes: implication on stealth, release characteristics and cytotoxicity. Int. J. Pharm. 431, 120-129.
44. Shi, J., Yan, W.W., Qi, X.R., Maitani, Y., Nagai, T., 2005. Characteristics and biodistribution of soybean sterylglucoside and polyethylene glycolmodified cationic liposomes and their complexes with antisense oligodeoxynucleotide. Drug Deliv. 12, 349-356. (Pubitemid 41572109)
45. Shimizu, K., Qi, X.R., Maitani, Y., Yoshie, M., Kawano, K., Takayama, K., Nagai, T., 1998. Targeting of soybean-derived sterylglucoside liposomes to liver tumors in rat and mouse models, Biol. Pharm. Bull. 21, 741-746. (Pubitemid 28374450)
46. Singh, M., Ariatti, M., 2003. Targeted gene delivery into HepG2 cells using complexes containing DNA, cationized asialoorosomucoid and activated cationic liposomes. J. Control. Release 92, 383-394. (Pubitemid 38366160)
47. Spanjer, H.H., Scherphof, G.L., 1983. Targeting of lactosylceramide- containing liposomes to hepatocytes in vivo. Biochim. Biophys. Acta 734, 40-47. (Pubitemid 14236722)
48. Szoka Jr., F., Papahadjopoulos, D., 1978. Procedure for preparation of liposomes with large internal aqueous space and high capture by reverse-phase evaporation. Proc. Natl. Acad. Sci. 75, 4194.
49. Tedesco, D., Tava, A., Galletti, S., Tameni, M., Varisco, G., Costa, A., Steidler, S., 2004. Effects of silymarin, a natural hepatoprotector, in periparturient dairy cows. J. Dairy Sci. 87, 2239-2247. (Pubitemid 38978827)
50. Unezaki, S., Maruyama, K., Takahashi, N., Koyama, M., Yuda, T., Suginaka, A., Iwatsuru, M., 1994. Enhanced delivery and antitumor activity of doxorubicin using long-circulating thermosensitive liposomes containing amphipathic polyethylene glycol in combination with local hyperthermia. Pharm. Res. 11, 1180-1185. (Pubitemid 24259860)
51. Valcavi, U., Monterosso, V., Caponi, R., Bosone, E., Wachter, W., Szejtli, J., 1993. Inclusion complexes with silybinin, their preparation and pharmaceutical compositions containing them. US Patent 5198430, 30 March.
52. Valenzuela, A., Barría, T., Guerra, R., Garrido, A., 1985. Inhibitory effect of the flavonoid silymarin on the erythrocyte hemolysis induced by phenylhydrazine. Biochem. Biophys. Res. Commun. 126, 712-718. (Pubitemid 15130439)
53. Wachter, W., Zaeske, H., 2000. Process for the Manufacture of Flavanolignan Preparation with Improved Release and Absorbability, Compositions Obtainable thereby and their Use for the Preparation of Pharmaceuticals. US Patent 6020384, 1 February.
54. Xu, X., Khan, M.A., Burgessa, D.J., 2012. A two-stage reverse dialysis in vitro dissolution testing method for passive targeted liposomes. Int. J. Pharm. 426, 211-218.
55. Xuan, T., Zhang, J.A., Ahmad, I., 2006. HPLC method for determination of SN-38 content and SN-38 entrapment efficiency in a novel liposome-based formulation, LE-SN38. J. Pharm. Biomed. Anal. 41, 582-588.
56. Yang, T., Cui, F.D., Choi, M.K., Choc, J.W., Chungb, S.J., Shimb, C.K., Kimb, D.D., 2007. Enhanced solubility and stability of PEGylated liposomal paclitaxel. In vitro and in vivo evaluation. Int. J. Pharm. 338, 317-326. (Pubitemid 46777245)
57. Zhang, L., Han, L., Sun, X., Gao, D., Qin, J., Wang, J., 2012. The use of PEGylated liposomes to prolong the circulation lifetime of salvianolic acid B. Fitoterapia 83, 678-689.
58. Zhang, Y., Qi, X.R., Gao, Y., Wei, L., Maitani, Y., Nagai, T., 2007. Mechanisms of comodified liver-targeting liposomes as gene delivery carriers based on cellular uptake and antigens inhibition effect. J. Control. Release 117, 281-290. (Pubitemid 46161882)